Lecanemab approval being pursued for Alzheimer’s Treatment

Japan-based pharmaceutical company Eisai Co., Ltd. recently anno0unced plans to seek full approval for its Alzheimer’s treatment drug lecanemab, a treatment that reportedly can slow progression of the disease in patients with early6 symptoms. In a post by Deena Beasley and Julie Steenhuysen yesterday on reuters.com, the background on Eisai’s pursuit of approval is discussed, along with observations on the timeline for CMS to grant approval. Check out the post here…

The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.